Peer to Peer Mentoring: Facilitating Individuals With Early Inflammatory Arthritis to Manage Their Arthritis: Peer Mentoring Program
This study has been completed.
Sponsor:
Sunnybrook Health Sciences Centre
Collaborator:
Canadian Arthritis Network
Information provided by (Responsible Party):
Dr. Mary Bell, Sunnybrook Health Sciences Centre
ClinicalTrials.gov Identifier:
NCT01054131
First received: January 21, 2010
Last updated: December 23, 2011
Last verified: December 2011
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Inflammatory arthritis (IA) is a major cause of long-term disability. Peer support may be a solution to the common problem of delayed treatment. Early peer support may result in improved use of therapy, higher self-efficacy, reduced anxiety, and improved coping in the first two years post-diagnosis. The whole intervention study comprises of two parts: The first part involves the development and testing of a peer mentor training initiative, which is called "Peer to Peer Mentoring: Facilitating Individuals with Early Inflammatory Arthritis to Manage their Arthritis - Peer Mentor Training". The second part, which is the focus of this study, involves the delivery of a one-on-one peer support intervention from a trained peer mentor to an individual newly diagnosed with EIA. The feasibility and acceptability of the program will be determined, as well as the health outcomes following the participation of the program.
| Condition | Intervention |
|---|---|
|
Early Inflammatory Arthritis Chronic Disease |
Behavioral: peer support |
| Study Type: | Interventional |
| Study Design: | Intervention Model: Single Group Assignment Primary Purpose: Supportive Care |
| Official Title: | Peer to Peer Mentoring: Facilitating Individuals With Early Inflammatory Arthritis to Manage Their Arthritis: Peer Mentoring Program |
Resource links provided by NLM:
Further study details as provided by Sunnybrook Health Sciences Centre:
Primary Outcome Measures:
- DMARD adherence [ Time Frame: 0, 3, 6 months ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- coping efficacy [ Time Frame: 0, 3 6 months ] [ Designated as safety issue: No ]
- self-management [ Time Frame: 0, 3, 6 months ] [ Designated as safety issue: No ]
- anxiety [ Time Frame: 0, 3, 6 months ] [ Designated as safety issue: No ]
- self efficacy [ Time Frame: 0, 3, 6 months ] [ Designated as safety issue: No ]
- social support [ Time Frame: 0, 3, 6 months ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 10 |
| Study Start Date: | January 2010 |
| Study Completion Date: | December 2011 |
| Primary Completion Date: | September 2011 (Final data collection date for primary outcome measure) |
Intervention Details:
-
Behavioral: peer support
A quasi-experimental, before and after study design will obtain data for planning and implementing a larger-scale study. Exposures and outcomes will be measured at baseline, 3 months (immediate post 12-week program) and 6 months (3 months post-program). Ten individuals with EIA will be recruited by brief screening interviews to ensure they meet inclusion criteria. Each pair of peer mentor and EIA participant will meet at SHSC for an initial contact. EIA participants will receive informational, emotional and appraisal support from trained peer mentors by telephone or neutral private location at a time convenient for both parties, at least once a week for 12 weeks.
Eligibility| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- Have EIA disease duration within 6-52 weeks
- At least 3 swollen joints, assessed by the treating rheumatologist, OR positive compression test for the metacarpophalangeal joints OR positive compression test for the metatarsophalangeal joints OR at least 30 minutes of morning stiffness
- Prescription of a DMARD/biologic by the treating rheumatologist
- Ability to speak and understand English without the aid of a secondary support person; AND
- Capability to provide informed consent.
Exclusion Criteria:
- IA disease duration less than 6 weeks or greater than 1 year
- Previous or ongoing DMARD or biologic treatment
- Inability to speak or read grade 6 English; AND
- Inability to provide informed consent
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01054131
Locations
| Canada, Ontario | |
| Sunnybrook Health Sciences Centre | |
| Toronto, Ontario, Canada | |
Sponsors and Collaborators
Sunnybrook Health Sciences Centre
Canadian Arthritis Network
Investigators
| Principal Investigator: | Mary J Bell, MD, FRCPC | Rheumatologist, Sunnybrook Health Sciences Centre |
More Information
No publications provided
| Responsible Party: | Dr. Mary Bell, Rheumatologist, Sunnybrook Health Sciences Centre |
| ClinicalTrials.gov Identifier: | NCT01054131 History of Changes |
| Other Study ID Numbers: | 420-2009 |
| Study First Received: | January 21, 2010 |
| Last Updated: | December 23, 2011 |
| Health Authority: | Canada: Ethics Review Committee |
Keywords provided by Sunnybrook Health Sciences Centre:
|
peer support peer mentor self-management early inflammatory arthritis chronic disease |
Additional relevant MeSH terms:
|
Arthritis Chronic Disease Joint Diseases |
Musculoskeletal Diseases Disease Attributes Pathologic Processes |
ClinicalTrials.gov processed this record on May 19, 2013